‘Sullivan’s Crossing’ Is Dominating My Netflix Feed. Why Have I Never Heard of It?

Linda Yaccarino’s next role after departing X as CEO will be another chief executive role at eMed Population Health, an AI startup building a tech platform for patients using GLP-1s.

Yaccarino was a longtime advertising executive at NBCUniversal, but left to join X as CEO for two years, where she managed to have a positive impact on the social network’s troubled ad revenue model, despite her and Elon Musk’s shared approach to minimizing content moderation.

Though Yaccarino does not have experience in health tech, eMed said in a press release that they sought her out for her “undeniable ability to negotiate new partnerships” — it certainly also helps that her tenure at X made her well-known in the tech world, drawing more eyes toward the startup.

eMed previously produced a tech platform that was designed to be used with at-home COVID-19 rapid antigen tests, guiding users through the process of administering these tests properly. Now, eMed is focused on GLP-1s, the class of drugs like Ozempic, which can be used for both weight management and treatment of type II diabetes.

“To be a leader in today’s healthcare marketplace, companies need to have a fearless tenacity that allows them to not only grow, but to also be brave enough to step forward and redefine an entire industry,” Yaccarino said in a press release. “We are very well-positioned to be that tenacious leader, striving toward our ultimate goal of improving global healthcare outcomes through our groundbreaking services and platforms.”